Skip to main content
Moogene Medi Co., Ltd. logo

Moogene Medi Co., Ltd. — Investor Relations & Filings

Ticker · 322970 ISIN · KR7322970005 KO Manufacturing
Open in API
Filings indexed 183 across all filing types
Latest filing 2025-11-06 AGM Information
Country KR South Korea
Listing KO 322970

About Moogene Medi Co., Ltd.

http://moogene.com/eng/

Moogene Medi Co., Ltd. is a biotechnology company specializing in nanomedicine and the development of advanced drug delivery systems. The company focuses on its proprietary Lipid Nanoparticle (LNP) carrier system and other nano-bio technologies to safely and effectively transport a range of therapeutic agents, including genes, chemicals, and proteins. Its primary mission is to create novel therapeutics for severe and incurable diseases. The development pipeline includes gene therapies for conditions such as cancer, metabolic diseases, and androgenic alopecia, utilizing technologies like CRISPR/Cas9 gene editing. Moogene Medi operates an aseptic, GMP-grade facility, providing end-to-end support from initial research to GMP-scale production for clinical studies.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 95% confidence The document is a detailed notice of a shareholders' meeting (주주총회소집공고) for a company named 무진메디, including the date, location, agenda items such as the appointment of a new non-executive director and stock option grants. It also contains extensive business overview, market analysis, and company status information. The document is not a full annual or quarterly financial report but rather a formal announcement to shareholders about convening a meeting and the matters to be discussed. It includes governance-related information and business updates but is primarily a meeting notice. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2025-11-06 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor presentation (IR) event scheduled for November 6, 2025. It details the event's date, location, participants, purpose, and agenda, but does not contain any financial statements or substantive financial data. The document is short (1017 characters) and serves to inform about the event rather than provide the presentation or report itself. Therefore, it fits the category of Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on company information and strategy.
2025-10-22 Korean
주주총회소집결의
Regulatory Filings Classification · 95% confidence The document is a resolution to convene a shareholders' meeting (주주총회소집 결의) scheduled for November 21, 2025. It details the meeting date, location, agenda items including the appointment of a non-executive director and granting stock options, and the board resolution date. The document is short (998 characters) and serves as an official announcement of the meeting convening rather than the meeting materials or results. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about the shareholders' meeting convening, not the meeting materials (AGM-R) or voting results (DVA).
2025-10-15 Korean
주주명부폐쇄기간또는기준일설정
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is very short (407 characters) and concerns the setting of a record date and shareholder register closure period for a shareholders' meeting. It includes specific dates and references a board resolution date. This is a typical announcement related to shareholder meeting logistics, specifically about the closure of the shareholder register to determine voting rights. It is not a full report or financial statement but an announcement about voting rights and shareholder register closure. Therefore, it fits best under Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-15 Korean
임상시험단계진입ㆍ종료(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Mujin Medi) regarding the approval of a Phase 1/2a clinical trial for a hair loss treatment. It follows the standard format for 'Autonomous Disclosure' (자율공시) in the Korean market, specifically detailing clinical trial progress. Since it does not fit into specific categories like financial reports, dividends, or shareholder meetings, and is a formal regulatory announcement of a material business event, it is classified as a Regulatory Filing (RNS).
2025-08-18 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) announcing the results of an Investor Relations (IR) meeting held by the company. It provides details on the date, location, attendees, and agenda, and confirms that the IR materials have been posted to the Korea Exchange's disclosure system. Per the 'Menu vs Meal' rule, since this is a brief announcement of an event and the availability of materials rather than the presentation itself, it is classified as a Report Publication Announcement (RPA).
2025-06-30 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.